Comparing second-line treatments for advanced thyroid cancer
Part of Cancer clinical trials.
This study looks at how well different second-line medicines work for people with a type of thyroid cancer that no longer responds to radioactive iodine. It is an observational study, so you continue your regular treatment and the researchers just collect information about your experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of differentiated thyroid cancer.
- Your cancer must have stopped responding to radioactive iodine treatment, and you must be starting your second line of treatment.
- You must be starting one of these medicines: lenvatinib, sorafenib, anlotinib, donafenib, apatinib, sunitinib, cabozantinib, pralsetinib, or a combination of dabrafenib and trametinib.
- You should not have had surgery to remove your thyroid cancer within 3 months after starting this new treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a targeted therapy pill combination (dabrafenib and trametinib) with cabozantinib or chemotherapy for people with a specific type of advanced thyroid cancer (differentiated thyroid cancer) that has a BRAF V600E mutation. It aims to find which treatment works better after previous treatments have stopped working.
This study compares two doses of lenvatinib (24 mg vs 10 mg per day) to see which works better for people with thyroid cancer that no longer responds to radioactive iodine. It's for those whose cancer is growing or causing symptoms.
This study compares two ways of suppressing a hormone that can make thyroid cancer grow. It aims to find which method is better for people with advanced thyroid cancer that cannot be removed by surgery.
This Phase 1 study tests how doctors plan a combination of two radiation approaches—external beam radiation and radioactive iodine—for thyroid cancer that is not fully responding to standard treatment. It may help people who still have iodine-avid tumor spots, but whose iodine uptake looks too low to work well with radioactive iodine alone.
This trial tests whether growing your tumor cells in a lab (as organoids) can help doctors pick the best drugs for advanced thyroid cancer that is hard to remove surgically. It's for people with different thyroid cancer types who have tumors growing outside the thyroid or into nearby areas.
This study looks at how different genetic types of advanced thyroid cancer respond to treatment in real-world settings. It may help doctors choose the best therapy for you based on your tumor’s genetic makeup.
Hear when a new Radioiodine-refractory Differentiated Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.